The randomised Ellipse trial has demonstrated significant blood glucose reductions with the glucagon-like peptide-1 receptor agonist liraglutide in children and adolescents with type 2 diabetes already taking metformin.
Research shows that growth hormone deficiency and central precocious puberty can occur in children several years after traumatic brain injury (TBI), even among those with normal pituitary function 1 year after the event.
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
Case history A girl aged 15 years and 2 months is referred to the Endocrine Clinic for short stature and delayed puberty. Read the patient information below and answer Question 1. Born in Malaysia [...]
Managing growth disorders: integrating technology into a personalised approach